Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Novartis
National Cancer Institute (NCI)
TG Therapeutics, Inc.
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Georgetown University
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center